Prominent features of the amino acid mutation landscape in cancer

PLoS ONE

Volumn 12, Issue 8, 2017, Pages

  Szpiech, Zachary A ^a   Strauli, Nicolas B ^a   White, Katharine A ^a   Ruiz, Diego Garrido ^a   Jacobson, Matthew P ^a   Barber, Diane L ^a   Hernandez, Ryan D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GLUTAMINE; HISTIDINE; LYSINE; AMINO ACID;

AMINO ACID SUBSTITUTION; ARTICLE; CELL HETEROGENEITY; MALIGNANT NEOPLASM; SOMATIC MUTATION; GENETICS; HUMAN; MUTATION; NEOPLASM; PRINCIPAL COMPONENT ANALYSIS; VALIDATION STUDY;

AMINO ACIDS; HUMANS; MUTATION; NEOPLASMS; PRINCIPAL COMPONENT ANALYSIS;

EID: 85028372899     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0183273     Document Type: Article

References (35)

1. Gillies RJ, Gatenby RA. Metabolism and its sequelae in cancer evolution and therapy. Cancer J. 2015; 21(2):88–96. https://doi.org/10.1097/PPO.0000000000000102 PMID: 25815848; PubMed Central PMCID: PMCPMC4446699.
2. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012; 481(7381):306–13. https://doi.org/10.1038/nature10762 PMID: 22258609; PubMed Central PMCID: PMCPMC3367003.
3. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976; 194(4260):23–8. PMID: 959840.
4. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, Andrews JM, et al. Signatures of mutation and selection in the cancer genome. Nature. 2010; 463(7283):893–8. https://doi.org/10.1038/ nature08768 PMID: 20164919; PubMed Central PMCID: PMCPMC3145113.
5. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013; 500(7463):415–21. https://doi.org/10.1038/ nature12477 PMID: 23945592; PubMed Central PMCID: PMCPMC3776390.
6. Tan H, Bao J, Zhou X. Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneity. Sci Rep. 2015; 5:12566. https://doi.org/10.1038/srep12566 PMID: 26212640; PubMed Central PMCID: PMCPMC4515826.
7. Anoosha P, Sakthivel R, Michael Gromiha M. Exploring preferred amino acid mutations in cancer genes: Applications to identify potential drug targets. Biochim Biophys Acta. 2016; 1862(2):155–65. https://doi.org/10.1016/j.bbadis.2015.11.006 PMID: 26581171.
8. Tsuber V, Kadamov Y, Brautigam L, Berglund UW, Helleday T. Mutations in Cancer Cause Gain of Cysteine, Histidine, and Tryptophan at the Expense of a Net Loss of Arginine on the Proteome Level. Bio-molecules. 2017; 7(3). https://doi.org/10.3390/biom7030049 PMID: 28671612.
9. Brunet JP, Tamayo P, Golub TR, Mesirov JP. Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A. 2004; 101(12):4164–9. https://doi.org/10.1073/pnas. 0308531101 PMID: 15016911; PubMed Central PMCID: PMCPMC384712.
10. Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017; 45(D1):D777–D83. https://doi.org/10.1093/nar/ gkw1121 PMID: 27899578; PubMed Central PMCID: PMCPMC5210583.
11. White KA, Grillo-Hill BK, Barber DL. Cancer cell behaviors mediated by dysregulated pH dynamics at a glance. J Cell Sci. 2017; 130(4):663–9. https://doi.org/10.1242/jcs.195297 PMID: 28202602; PubMed Central PMCID: PMCPMC5339414.
12. Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer. 2005; 5(10):786–95. https://doi.org/10.1038/nrc1713 PMID: 16175178.
13. Grillo-Hill BK, Choi C, Jimenez-Vidal M, Barber DL. Increased H(+) efflux is sufficient to induce dyspla-sia and necessary for viability with oncogene expression. Elife. 2015; 4. https://doi.org/10.7554/eLife. 03270 PMID: 25793441; PubMed Central PMCID: PMCPMC4392478.
14. Parks SK, Chiche J, Pouyssegur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer. 2013; 13(9):611–23. https://doi.org/10.1038/nrc3579 PMID: 23969692.
15. Webb BA, Chimenti M, Jacobson MP, Barber DL. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer. 2011; 11(9):671–7. https://doi.org/10.1038/nrc3110 PMID: 21833026.
16. Zheng Y, Cui Q. Microscopic mechanisms that govern the titration response and pKa values of buried residues in staphylococcal nuclease mutants. Proteins. 2017; 85(2):268–81. https://doi.org/10.1002/prot.25213 PMID: 27862310.
17. Zhang Z, Witham S, Alexov E. On the role of electrostatics in protein-protein interactions. Phys Biol. 2011; 8(3):035001. https://doi.org/10.1088/1478-3975/8/3/035001 PMID: 21572182; PubMed Central PMCID: PMCPMC3137121.
18. Cho W, Stahelin RV. Membrane-protein interactions in cell signaling and membrane trafficking. Annu Rev Biophys Biomol Struct. 2005; 34:119–51. https://doi.org/10.1146/annurev.biophys.33.110502. 133337 PMID: 15869386.
19. Stahelin RV. Lipid binding domains: more than simple lipid effectors. J Lipid Res. 2009; 50 Suppl:S299–304. https://doi.org/10.1194/jlr.R800078-JLR200 PMID: 19008549; PubMed Central PMCID: PMCPMC2674730.
20. Ubersax JA, Ferrell JE Jr. Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell Biol. 2007; 8(7):530–41. https://doi.org/10.1038/nrm2203 PMID: 17585314.
21. Chimenti MS, Khangulov VS, Robinson AC, Heroux A, Majumdar A, Schlessman JL, et al. Structural reorganization triggered by charging of Lys residues in the hydrophobic interior of a protein. Structure. 2012; 20(6):1071–85. https://doi.org/10.1016/j.str.2012.03.023 PMID: 22632835; PubMed Central PMCID: PMCPMC3373022.
22. Carson JD, Van Aller G, Lehr R, Sinnamon RH, Kirkpatrick RB, Auger KR, et al. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem J. 2008; 409(2):519–24. https://doi.org/10.1042/BJ20070681 PMID: 17877460.
23. Huang CH, Mandelker D, Gabelli SB, Amzel LM. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha. Cell Cycle. 2008; 7(9):1151–6. https://doi.org/10.4161/cc.7.9.5817 PMID: 18418043; PubMed Central PMCID: PMCPMC3260475.
24. Meyer DS, Koren S, Leroy C, Brinkhaus H, Muller U, Klebba I, et al. Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R. Oncogenesis. 2013; 2:e74. https://doi.org/10.1038/oncsis.2013.38 PMID: 24080956; PubMed Central PMCID: PMCPMC3816227.
25. Choi CH, Webb BA, Chimenti MS, Jacobson MP, Barber DL. pH sensing by FAK-His58 regulates focal adhesion remodeling. J Cell Biol. 2013; 202(6):849–59. https://doi.org/10.1083/jcb.201302131 PMID: 24043700; PubMed Central PMCID: PMCPMC3776353.
26. Frantz C, Barreiro G, Dominguez L, Chen X, Eddy R, Condeelis J, et al. Cofilin is a pH sensor for actin free barbed end formation: role of phosphoinositide binding. J Cell Biol. 2008; 183(5):865–79. https://doi.org/10.1083/jcb.200804161 PMID: 19029335; PubMed Central PMCID: PMCPMC2592832.
27. Webb BA, White KA, Grillo-Hill BK, Schonichen A, Choi C, Barber DL. A Histidine Cluster in the Cytoplasmic Domain of the Na-H Exchanger NHE1 Confers pH-sensitive Phospholipid Binding and Regulates Transporter Activity. J Biol Chem. 2016; 291(46):24096–104. https://doi.org/10.1074/jbc.M116. 736215 PMID: 27650500; PubMed Central PMCID: PMCPMC5104935.
28. DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC, et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol. 2002; 9 (1):12–6. https://doi.org/10.1038/nsb730 PMID: 11753428.
29. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neo-plasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011; 60(3):397–411. https://doi.org/10.1136/gut.2010.217182 PMID: 21036793; PubMed Central PMCID: PMCPMC3040598.
30. Nishi A, Milner DA Jr., Giovannucci EL, Nishihara R, Tan AS, Kawachi I, et al. Integration of molecular pathology, epidemiology and social science for global precision medicine. Expert Rev Mol Diagn. 2016; 16(1):11–23. https://doi.org/10.1586/14737159.2016.1115346 PMID: 26636627; PubMed Central PMCID: PMCPMC4713314.
31. Alfarouk KO, Stock CM, Taylor S, Walsh M, Muddathir AK, Verduzco D, et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int. 2015; 15:71. https://doi.org/10.1186/s12935-015-0221-1 PMID: 26180516; PubMed Central PMCID: PMCPMC4502609.
32. Alfarouk KO, Verduzco D, Rauch C, Muddathir AK, Adil HH, Elhassan GO, et al. Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question. Oncoscience. 2014; 1(12):777–802. https://doi.org/10.18632/oncoscience.109 PMID: 25621294; PubMed Central PMCID: PMCPMC4303887.
33. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer. 2012; 12(7):487–93. https://doi.org/10.1038/nrc3298 PMID: 22695393; PubMed Central PMCID: PMCPMC4122506.
34. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010; 7(4):248–9. https://doi.org/10.1038/ nmeth0410-248 PMID: 20354512; PubMed Central PMCID: PMCPMC2855889.
35. Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinformatics. 2010; 11:367. https://doi.org/10.1186/1471-2105-11-367 PMID: 20598126; PubMed Central PMCID: PMCPMC2912887.